Compare · DFTX vs HAPP
DFTX vs HAPP
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Happiness Development Group Limited (HAPP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and HAPP operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.57B, about 172.6x HAPP ($14.9M).
- DFTX has hit the wire 6 times in the past 4 weeks while HAPP has been quiet.
- DFTX has more recent analyst coverage (4 ratings vs 0 for HAPP).
- Company
- Definium Therapeutics Inc.
- Happiness Development Group Limited
- Price
- $23.59+3.10%
- $4.52-2.80%
- Market cap
- $2.57B
- $14.9M
- 1M return
- +8.48%
- -
- 1Y return
- +208.43%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 6
- 0
- Recent ratings
- 4
- 0
Happiness Development Group Limited
Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. Happiness Biotech Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest HAPP
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form EFFECT filed by Happiness Development Group Limited
- SEC Form F-3 filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form SC 13G filed by Happiness Development Group Limited
- SEC Form SC 13G filed by Happiness Development Group Limited
- SEC Form 20-F/A filed by Happiness Development Group Limited (Amendment)
- SEC Form 6-K filed by Happiness Development Group Limited